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Molecules that Target beta-Amyloid
Cliff I. Stains, Kalyani Mondal, and Indraneel Ghosh

Abstract
The devastating effects of Alzheimer’s and related amyloidogenic diseases have inspired the synthesis and evaluation of numerous ligands to understand the molecular mechanism of the aggregation of the beta-amyloid peptide. Our review focuses on the current knowledge in this field with respect to molecules that have been demonstrated to interact with either oligomeric or fibrillar forms of the betaamyloid peptide. We describe natural proteins, peptides, peptidomimetics, and small molecules that have been found to interfere with
beta-amyloid aggregation. We also detail recent efforts in selecting molecules that target beta-amyloid isolated from antibody, protein,
and peptide libraries. These new molecules will likely aid in deciphering the details of the aggregation pathway for the beta-amyloid peptide and provide reagents that may stabilize relevant oligomeric intermediates which likely have bearing on the pathophysiology of Alzheimer’s disease. Moreover, the described anti-amyloid molecular toolbox will also provide an avenue for designing new diagnostic and
therapeutic reagents.
Keywords: Alzheimer’s, amyloid, peptides, proteins, small molecules

Introduction
The abnormal assembly of proteins is implicated in over
30 human disorders, which include Alzheimer’s disease (Aβ1–
42), Parkinson’s disease (α-synuclein), and dialysis related amyloidosis (β2-microglobulin).1–4 Alzheimer’s disease (AD) is
perhaps best characterized by the extracellular deposits of the
39–42 amino acid amyloid-β peptides (Aβ) along with neurofibrillary tangles in the brains of patients. Aβ peptides arise from
cleavage of the extracellular portion of the transmembrane
amyloid-precursor protein (APP) by β- and γ-secretases.5–7
The elucidation of the genetic, biochemical, and biophysical
origins of Alzheimer’s disease (AD) remains a complex and
formidable challenge. The toxicity of processed Aβ peptide
may include a combination of apoptosis,8 disrupted Ca2+ homeostasis,9 toxic radicals,10, 11 and complement formation.12
Over the past decade Selkoe,13 Lansbury,14 Teplow,15 Kelly,4
Dobson,16, 17 and Prusiner,18 among many others have helped
establish a general nucleation dependent paradigm for fibril
formation (Figure 1). These ongoing experiments have also
demonstrated that the rate of fibrillization and the morphology
of the final fibrillar state are strongly influenced by environmental factors (pH, salt, temperature, agitation, etc.); chemicals
(proteins, lipids, cholesterol, metals, etc.); and by the nature
of the seeding agent.14 In the case of Aβ, evidence from both
in vitro19, 20 and in vivo21, 22 studies strongly suggest that soluble oligomeric Aβ forms with β-sheet secondary structure are
responsible for neurological toxicity (Figure 1).22, 23 In this review we will briefly present current structural paradigms in AD
followed by a discussion of the molecular approaches towards
targeting oligomers and fibrils.
The presence of amyloid plaque in the postmortem brains
of patients suffering from Alzheimer’s disease led to the hypothesis that these extracellular plaques were pathological to
the neuronal cells. This view was further confirmed by in vi-

tro experiments where Aβ fibrils upon incubation with rat hippocampal cultures were found to be toxic to these neuronal
cells.24–26 However, much current work with amyloidogenic
proteins has led to a paradigm shift towards an oligomeric
toxic species. The evidence for a toxic oligomeric intermediate rests on the following experiments: firstly, there seems to
be a stronger correlation between “soluble Aβ” (monomer and
oligomers of Aβ) in the brain and early cognitive dysfunction
than there is between the Aβ deposits and clinical severity of
AD;27–30 secondly, transgenic mice that overexpress APP exhibited neuronal and behavioral abnormalities before amyloid
plaques were detected31, 32 and thirdly, soluble oligomers of Aβ
were found to be toxic to cell cultures33, 34 and affected hippocampal long term potentiation when injected in transgenic
mice.21, 35 Haass & Selkoe have also argued that Aβ aggregates present less surface area for interaction with the neurons as compared to the soluble intermediates which can easily diffuse into synaptic clefts and hence are better candidates
for causing neuronal dysfunction.36 Several of these intermediates have been validated in aggregation studies of purified Aβ,
whereas some have also been isolated and purified from cell
cultures and brains of transgenic mice (Table 1).
Interestingly, studies in the similar Huntington’s Disease,
showed significantly less cell death when fibrils of polyglutamine oligomers of the huntingtin protein were present.37, 38
This has led many researchers to postulate that in some cases
the fibrillar aggregates may protect normal cells against toxic
oligomeric intermediates.39, 40 However, deposits of Aβ in AD
brain do show surrounding dystrophic neuritis indicating that
insoluble aggregates may be contributing to neuronal injury.41
It is also possible that the large aggregates are in slow equilibrium with surrounding soluble oligomers which may be the actual toxic species (Figure 1). Although, it is not clear that oligomers lie in the same pathway as fibrils as small molecules
which inhibit oligomer formation but not fibril formation have
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Figure 1. Model for the fibrillogenesis pathway for Aβ.13–18
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been described.42 Hence at the current time the true culprit in
these diseases, whether fibrillar or oligomeric, remains to be
unequivocally established. Studies on model protein aggregates are also aiding in this effort.16, 43–47 Many experiments
are underway to provide a molecular level understanding of
the Aβ oligomers and the data are summarized in Table 1. This
data clearly suggests that even the actual dimensions of these
oligomers, whether 2 nm, 20 nm, or even micellar, still remains
to be established. The data presently suggest that it is very
likely that multiple oligomeric species are implicated in the fibrillization pathway.
In comparison to our understanding of the oligomers, ongoing solid state NMR studies from Tycko are rapidly unraveling
a true molecular description of the Aβ1–40 fibrils. Current work
suggests that the amyloid structure favors a C2z symmetry48
that is primarily stabilized by hydrophobic interactions involving L17, F19, A21, A30, I32, L34, and V36 at the “internal quaternary interface” (interface between β-sheets within a single
layer of Aβ molecules) and I31, M35, and V39 at the “external
quaternary interface” (interface between β-sheets of two separate layers of Aβ molecules) (Figure 2).49 Salt bridges formed
between K28 and D23 also appear to be important for stability,
as a lactam crosslink between K28 and D23 has been shown
to delay fibrillization.50 Once formed, the fibril structure may
exclude water as significant changes in structure were not observed when water was removed by freeze-drying. In contrast
to some earlier models, Tycko has proposed that native amyloid fibrils are more commonly composed of parallel β-sheets
whereas the antiparallel arrangement may be predominant in
fibrils formed from short peptides.49 Emerging models of polyglutamine fibrils may also illuminate this issue.51
Further biophysical characterization of these intermediates will allow for a structure guided discussion of how different known ligands interact with Aβ and provide a rational template for either stabilizing or disrupting these oligomers. It is
perhaps possible that the ligands that target specific oligomers
of Aβ will provide a method for trapping these intermediates
for structural elucidation. The following discussion will entail
a review of amyloid (oligomeric or fibrillar) binding molecules
and new molecular approaches for preventing Aβ aggregation
and toxicity, which has been the focus of most studies to date.
Our review is divided into the following five sections: 1) Natu-
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Table 1. Oligomers of Aβ.
Aβ oligomers

Characteristic feature

Method of preparation

Ref.

SDS stable Aβ 	
These oligomers are resistant to SDS and protease
SDS stable dimer and trimers of Aβ1–40 were
52, 53
dimers and
(insulin-degrading enzyme, IDE). They were found
detected in cellular media of Chinese hamster
trimers
to affect synaptic structure and function.
ovary cells which were transfected with the
		
APP gene to overexpress Aβ.
 	 	 	 
Protofibrils
Curvilinear, metastable intermediates which disappear 	 Aβ1–40 (500 μM) upon incubation in phosphate
12, 16, 42, 43
as fibrils are formed, usually 4-10 nm diameter and up 	 buffer, pH 7.4 at room temperature for 1–2 days
to 200 nm in length; have been shown to cause 	
showed equivalent amounts of protofibrils and
decrease in levels of reduced MTT in rat neuronal 	
low molecular weight oligomers; Aβ1–40 (50 μM)
culture.
when incubated with calmidazolium chloride
		
(100 μM) for 2 days predominantly formed protofibrils.
 	 	 	 
Annular 	
Doughnut like structures with inner diameter of 	
The arctic mutant of Aβ1–40 (E22G) formed
54, 55
assemblies
2.0–2.5 nm and outer diameter of 8–12 nm.
annular intermediate species more rapidly and
		
to a greater extent as compared to the wild type
		
Aβ. These were separated by SEC. Low molecular
		
weight oligomers of Aβ1–42 fractionated by SEC
		
consisted of pentamers/hexamers and formed
		
beaded structures.
 	 	 	 
Amylospheroids 	 Spherical oligomers of 3–20 nm in diameter
Aβ1–40 (350 μM) when rotated slowly using a 	
34
(ASPD)
observed in aggregating samples of both Aβ1–40
rotating cultivator at 37 °C for 5–7 days, formed
and Aβ1–42. Spheroids of size 10–15 nm were 	
ASPDs. Aβ42 ASPDs were prepared by rotating
toxic to primary cultures of neuronal cells from
the samples at 4 °C for 8–10 h.
rat brain. ASPDs of size <10 nm were non-toxic.
 	 	 	 
Aβ-derived 	
Globular intermediates (5–6 nm in diameter), 	
ADDLs of Aβ1–42 have been prepared by
23, 33
diffusible 	
smaller than the annular assemblies. These have
incubating Aβ with clusterin for 24 h. In
ligands 	
been shown to kill mature neurons at nanomolar
clusterin-free solution, ADDLs of Aβ were prepared
(ADDLs)
concentrations. Also evoked neurological 	
by incubating a 100 μM solution of Aβ1–42 at 4–8 °C
dysfunctions well before cellular degeneration.
for 24 h or by diluting an Aβ solution to 50 nM at
		
37 °C. However, preparation of these species may
		
be dependant on specific conditions such as the use
		
of DMEM-F12 media (without phenol red) and the
		
lack of agitation during incubation.
 	 	 	 
Aβ*56
Dodecameric assembly of Aβ1–42 extracted and purified 	 Aβ*56 was separated by a high-fidelity extraction
56
from extra-cellular fraction from 6 month old transgenic procedure that separated protein into extra-cellular,
mice. Aβ*56 disrupted memory when administered to 	 intra-cellular, membrane enriched and insoluble
young rats.
fractions.

ral protein ligands that interact with Aβ, 2) Inhibition with modified peptides and peptidomimetics derived from the parent Aβ
Sequence, 3) Targeting Aβ with antibodies, 4) Targeting amyloid with in vitro selected peptides and proteins, and 5) Targeting Aβ with small molecules.
1. Natural Protein Ligands that Interact with Aβ
Though the mechanism of toxicity of Aβ in the cellular environment is still not clearly understood, numerous experiments
have been conducted to determine possible natural protein
binding partners of Aβ. Some of these natural ligands may be
a missing link between Aβ accumulation and cellular toxicity
(Table 2). A few of these interacting proteins which have been
studied in greater detail are discussed below.
The conventional yeast two-hybrid system, used to detect
protein–protein interactions in vivo, has been applied to Aβ.57
This system was able to specifically report on the interaction
of Aβ monomers in the yeast nucleus. A control bait protein
which contained double Phe to Thr substitutions, at residues
19 and 20 of the hydrophobic core, did not produce apprecia-

ble signal, indicating that the observed Aβ interactions were
likely specific.
Subsequently a similar yeast two-hybrid system was also
used to identify an endoplasmic-reticulum associated binding
protein (ERAB) from human brain and HeLa cell cDNA libraries.58 ERAB was shown to co-precipitate with Aβ and suppression of ERAB activity led to a decrease in cellular toxicity of Aβ.
This protein was identified as an alcohol dehydrogenase and
was later termed Aβ-binding alcohol dehydrogenase or ABAD.
A crystal structure of Aβ-bound ABAD has been solved.59 This
crystal structure shows that the active site is severely perturbed such that NAD binding is prevented. An ABAD derived
peptide was shown to suppress Aβ toxicity while the overexpression of ABAD in the presence of Aβ led to an increase in
oxidative stress in transgenic mice. An ELISA based screen
has identified small molecule inhibitors of the Aβ-ABAD interaction.60 The most potent of these inhibitors had an IC50 value
of <10 μM but its ability to decrease the cytotoxicity of Aβ remains to be demonstrated.
The early observations of increased phosphorylation of proteins in Alzheimer’s patients led to the hypothesis that Aβ may
directly perturb the activities of certain kinases. Indeed, the ac-

1678

S ta i n s , M o n d a l , & G h o s h

in

C h e m M e d C h e m 2 (2007)

Figure 2. Structural model for the protofilament in Aβ1–40 fibrils prepared with gentle agitation a) All-atom representation of a pair of peptide molecules. Residues 10–22 and 30–40 have β-strand conformations, forming two separate in-register, parallel β-sheets. The protofilament is a fourlayered β-sheet structure with C2 symmetry about its long axis. Double-headed arrows indicate side chain–side chain and side chain–backbone
contacts established by 2D 13C-13C NMR measurements or 15N-13C dipole-dipole couplings. b) Average structure resulting from ten independent
molecular dynamics/energy minimizations runs on a cluster of twelve peptides, with interatomic distance and backbone torsion angle restraints
dictated by solid-state NMR data. The four-layered β-sheet structure is stabilized primarily by hydrophobic interactions in the core of the protofilament. Polar and charged side-chains are on the exterior, with the exception of oppositely charged K28 and D23 side-chains, which form salt
bridges. c) and d) Cartoon representations with residues 12–21 and 30–40 shaded. (Reprinted with permission from Cambridge University Press)

tivities of purified casein kinase I and II (CKI and II) have been
shown to be increased in a concentration dependent manner
by Aβ when monitoring phosphorylation of casein.61 Overexpression of a constituently active form of CKI has been shown
to increase the amount of Aβ in brain tissue cultures.86 Three
different CKI-specific inhibitors were shown to decrease the
amount of Aβ produced. This approach has the potential for
identifying novel therapeutics for the treatment of Alzheimer’s
if the CKI/Aβ interaction correlates with cognitive failure. It is
still to be established whether the observed effects are directly
or indirectly mediated by Aβ in a physiological context.
The activity-dependent neuroprotective protein (ADNP)
was discovered by screening cDNA libraries by antibody mat-

uration. A very short eight amino-acid segment of this protein,
NAPVSIPQ, was shown to protect neuronal cells against Aβ at
femtomolar concentrations.63, 87 A study has shown that intranasal administration of this peptide can significantly reduce the
levels of Aβ in transgenic mice model of Alzheimer’s.9 Again it
is very possible that this peptide does not function by direct interaction with Aβ.
Transthyretin, a protein in the cerebral fluid, was found to
bind to Aβ through fractionation of an Aβ-binding activity.85
Subsequently, transgenic mice containing a mutation in the
APP gene predisposing them to early onset AD, the Swiss mutation, were found to overexpress transthyretin.88 This overexpression correlated with a decrease in the progression of AD
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Table 2. Biomolecules that bind Aβ.
Biomolecule

Method of Discovery/Evidence

Aβ-Binding Alcohol Dehydrogenase
Yeast two-hybrid screen using a human brain cDNA library
Aβ-Related Death-Inducing Protein
Yeast two-hybrid screen using a human brain cDNA library
Activity-Dependent Neuroprotective
Isolated from a cDNA library from mouse embryonic carcinoma cells
Protein
induced to differentiate into neurons using retinoic acid
α1-Antichymotrypsin
Antigen maturation of a cDNA library
α-7 Nicotinic Acetylcholine Receptor
Co-immunoprecipitation from human brain tissue
α-Ketoglutarate
Enzyme activity in isolated rat brain mitochondria
β2-Macroglobin
Yeast two-hybrid screen using a HeLa cDNA library
Amyloid Precursor Protein
Co-precipitation with Aβ in rat hippocampal cultures
Apolipoprotein E4
Amyloid deposition in a mice model correlated to Apo E4 expression
Apolipoprotein J
Affinity purification from cerebral spinal fluid by immobilized Aβ
Casein Kinase I and II
In vitro phosphorylation assay using casein
Catalase
In vitro binding assay to monitor catalase binding
Collagen-like Alzheimer Amyloid Plaque 	
Isolation of an Aβ-associated antigen further fractionation and identification
Component
using proteolytic cleavage and protein sequencing
Cytochrome Oxidase
Enzyme activity in isolated rat brain mitochondria
Formyl Peptide Receptor Like-1
Chemotaxis of monocytes and Ca2+ mobilization
Gelsolin
ELISA assay for Aβ-binding to immobilized gelsolin
Heat Shock Proteins 70 and 90
In vitro inhibition of Aβ assembly
Insulin Receptor
Competes with insulin for binding to the insulin receptor
Integrins
Inhibition of cell adhesion, of human neuroblastoma cells, to fibronectin by Aβ
N-Methyl-D-Aspartate Receptors
Internalization of Aβ in cultured hippocampal slices
p75 Neurotrophin Receptor
Co-immunoprecipitation, using NIH-3T3 cells, of radiolabeled Aβ
Protein Kinase C
Tissue culture phosphorylation assay
Pyruvate Dehydrogenase
Enzyme activity in isolated rat brain mitochondria
Receptor for Advanced Glycation End 	
Isolation of a Aβ-binding activity and protein sequencing
Products		
Scavenger Receptors
Microglial uptake
Serpin-Enzyme Complex Receptor
Competitive inhibition of a radiolabeled ligand binding by Aβ in human hepatoma cells
Tau
Production of antibodies, using fibrils, which recognize tau
Transthryetin
Isolation of an Aβ-binding activity from cerebral spinal fluid and protein sequencing

symptoms such that disease onset was delayed. Forty-seven
individual point mutants of transthyretin have been analyzed
for Aβ-binding and inhibition of fibril formation.89 All but two
mutants, G42 and P55, bound Aβ, localizing the Aβ-binding
activity to this region. Studies suggest that transthyretin decreases the rate of fibril formation by decreasing the lateral association of fibrils as well as decreasing the rate of elongation
of fibrils.90 These data would indicate that, at concentrations of
2 μM transthyretin and 140 μM Aβ, transthyretin binds to the fibrillar form of Aβ arresting the formation of plaques. This study
is quite interesting, given that transthyretin itself is directly implicated in a different misfolding disease and one of the few instances where small molecules are known to inhibit aggregation by stabilizing the native state.91
From the above studies with possible natural protein ligands of Aβ, it is clear that there are many possible candidate
proteins that directly or indirectly interact with Aβ and modulate its activity. With a growing list of candidate proteins the
physiological role of Aβ will likely be established, resulting in
new methods for diagnosing and possibly treating AD. Structural details of true and potent Aβ bound complexes will likely
provide the necessary molecular templates for the design of
useful diagnostics and therapeutics as has been realized for
transthyretin.

Ref.
58
62
63
64
65
66
67
8
68, 69
70
61
71
72
66
73
74
75
76
77
78
79
80
66
81
82
83
84
85

2. Inhibition with Modified Peptides and Peptidomimetics
Derived from the Parent Aβ Sequence
Several elegant strategies have been used to rationally design peptidic inhibitors of Aβ aggregation, some of which are
discussed in detail (Table 3). Many of these approaches rely
on using fragments of the parent Aβ sequence as recognition
elements in a dominant negative fashion. Typically, fibril disrupting chemical elements are incorporated into Aβ derived
peptides in the form of N- or C-terminal modifications, conformationally constrained amino acids, or modifications to the
peptide backbone. These concepts have also been applied to
D-amino acid variants of the parent Aβ sequence. These different molecular design strategies are discussed below.
N- and C-terminal modifications
Inhibitors of fibril formation based on the hydrophobic region of Aβ are the most prevalent. Initial work in this area
identified the KLVFF motif92 as capable of inhibiting fibril formation. A variant of this core domain (Table 3 a) containing a polycationic disrupting region appended to the C terminus, KLVFFKKKKKK, was shown to increase the rate of
fibril formation and cell viability.93, 94 The rate of fibril forma-
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Table 3. Designed peptide inhibitors of Aβ.
Aβ(1–42): DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
a) N- and C-Terminal Modifications:
Peptide
Activity
KLVFF
Inhibited fibril formation
KLVFFKKKKKK
Kd: 40 μM, SPR
KLVFFKKKK
Kd: 37 μM, SPR
KLVFFKK
Kd: 80 μM, SPR
KLVFFEEEKKK
Kd: 1.3 mM, SPR
KKKKLVFF
Kd: 180 μM, SPR

DDX3

Structure
KLVFF
KLVFFKKKKKK
KLVFFKKKK
KLVFFKK
KLVFFEEEKKK
KKKKLVFF

Reduced toxicity in neuroblastoma cells		

Ref.
92
94
94
94
94
94

101

RIIGL
Inhibited fibril formation and toxicity
RIIGL
95
Was toxic in cellular assays
95
PrIIGL
PrIIGL
 	 	 	 
b) Conformationally Constrained Peptides:
Peptide
Activity
Structure
Ref.
iAβ5
Inhibited fibril formation, disassembled fibrils, 	
LPFFD
96
and reduced toxicity

AMY-1

No fibril formation after 4.5 months		

97

AMY-2

Rapid formation of large nonfibrillar aggregates		

97

 	 	 	 
c) Backbone Modifications:
Peptide
Activity
Structure
Ref.
Aβ16–22m
IC50: 420 μM using ThT
KNMeLVNMeFFNMeAE
98
NMeGly25
Similar to parent sequence
99
NMeGSNKGAIIGLM
NMeGly33
Inhibited fibril formation and reduced toxicity
GSNKGAIINMeGLM
99
NMeLeu34
Altered fibril morphology
GSNKGAIIGNMeLM
99

Aβ16–20e
Inhibits fibril formation and disassembles fibrils		
100
 	 	 	 

d) d-Amino Acid Peptides:
Peptide
Activity

Structure

Ref.

SEN 301

Produced multiple types of fibrils		

102

SEN 302

Least effective at reducing toxicity		

102
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Table 3. Designed peptide inhibitors of Aβ (continued).
Aβ(1–42): DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
SEN 303

Significantly reduced toxicity		

102

SEN 304

Significantly reduced toxicity		

102

SEN 305

Reduced toxicity to a lesser extent		

102

SEN 306

Reduced toxicity to a lesser extent		

102

SEN 307

Reduced toxicity to a lesser extent		

102

D-KLVFF

Inhibited fibril formation

103

PPI-433

Inhibited fibril formation and reduced toxicity		

D-KLVFF

tion increased with the number of lysine residues as follows:
KLVFFKK<KLVFFKKKK<KLVFFKKKKKK. The effect of charge
distribution and the orientation of the disrupting element was
also verified using KLVFFEEEKKK and KKKKLVFF. Both of
these peptides bound with less affinity to Aβ as determined by
SPR. The ability of these peptides to accelerate fibril formation
while decreasing toxicity is very intriguing, and suggests that
the new fibrils are not toxic or that they are no longer in equilibrium with the toxic oligomeric intermediates. A peptide corresponding to Aβ31–34 when appended to a N-terminal propionyl group (PrIIGL)95 was shown to form fibers and was toxic
to neuroblastoma cells. However, replacement of the propionyl group with an arginine (RIIGL) resulted in a peptide which
inhibited fibril formation and reduced toxicity of Aβ, possibly
sequestering the toxic oligomeric species and preventing interactions at the cell membrane. The above studies are quite
significant as they suggest multiple new routes to interfere with
Aβ assembly and may also be starting points for designing reagents that trap and stabilize intermediates that can be further
studied at the molecular level.

104

Conformationally constrained peptides
Building on the observation that the hydrophobic core of
Aβ was capable of inhibiting fibril formation, a conformationally constrained β-sheet breaker peptide has been designed.96
The peptide, iAβ5, contains a single proline residue in the hydrophobic recognition sequence which is thought to disrupt fibril formation through unfavorable steric interactions or alternatively by redirecting Aβ assembly in alternate nontoxic
arrangements. This peptide was reported to disassemble fibrils in vitro and to increase cell viability.
A new class of conformationally constrained peptides which
contained α,α-disubstituted amino acids (Table 3 b) have been
synthesized.97 These α,α-disubstituted amino acids were incorporated in such a way that one face of the peptide would
be sterically blocked. The peptide AMY-1 was shown to abrogate fibril formation for up to 4.5 months, whereas AMY-2 was
shown to produce nonfibrillar aggregates. The authors suggest
that this difference in activity may be attributed to the positioning of the hydrophilic tails in each peptide, such that the polyly-

1682
sine tail at the C terminus disrupts amyloid aggregation by interfering with committed assembly steps within the N-terminal
hydrophobic region.
Another interesting approach in this area of Aβ mimetics
is the substitution of alternating amide hydrogens with methyl
groups (Table 3 c). This approach in principle serves to cap
oligomeric domains and prevent the β-sheet propagation necessary for Aβ fibrillization. Furthermore, these N-methylated
peptides tend to have increased solubility (by preventing self
aggregation), increased resistance to proteolytic degradation,
and the possibility for increased blood-brain barrier penetration. Meredith and co-workers designed inhibitors based on the
much studied hydrophobic core Aβ motif KLVFFAE, containing
N-methylated amino acids.98 These peptides were found to inhibit fibril formation and disassemble preformed fibrils in vitro. The most potent inhibitor contained alternating sites of Nmethylation, Aβ16-22m. N-methylated Aβ derived peptides
have also been reported by Doig based on Aβ25–35 (GSNKGAIIGLM).99 The authors showed that NMeGly25 had no activity and actually showed similar aggregation and toxicity levels as that of the wild-type sequence. However, NMeGly33 was
shown to completely inhibit fibril formation, disassemble preformed fibrils, and reduce cellular toxicity. These results would
imply that the position of N-methylation is crucial for efficacy
and likely maps to a critical region of the growing amyloid fibril
(Table 3). Meredith and co-workers have also investigated the
effect of replacing the amide backbone with ester bond surrogates at alternating positions.100 The peptide, Aβ16-20e, was
synthesized and shown to inhibit fibril formation and disassemble fibrils in vitro. This ester containing peptide likely functions
by preventing hydrogen-bond propagation as seen in the alternating N-methylation approach. What is also very interesting
is the reported disassembly of pre-existing fibers, which may
suggest that many of these peptides can bind at the end of the
fibrils and possibly serve to influence the thermodynamic equilibrium between oligomers and fibrils.
D-Amino acid peptides
Doig and coworkers systematically explored the structure–activity relationship of numerous peptides based on
the KLVFFA sequence.102 The initial library of KLVFFA peptides revealed that peptides containing the core LVFFL motif were the most effective at inhibiting fibrillization. Efficacy
was increased when peptides were constructed entirely from
D-amino acids and singly methylated at the first and fifth positions or doubly methylated at both positions. Using this information the authors developed four new libraries to ascertain the effects of the position of N-methylation and amino
acid preference. The authors found that large branched hydrophobic side chains were preferred at positions 1–4 and
that a single N-methylated site was sufficient for fibril inhibition. All peptides from this final compound library were
shown to decrease toxicity in PC12 cells using the MTT assay. The most potent compound, SEN 304, was determined
to be more active than the β-sheet breaker peptide96 as determined by ThT and MTT assays.
Other interesting approaches105 have targeted Aβ utilizing peptides based on the GxFxGxF scaffold expected to interact with the C terminus of Aβ. The most active compound
RGTWEGKW was shown to inhibit fibril formation and re-
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duce cellular toxicity. The authors propose that alternating hydrophilic-hydrophobic nature of this peptide may help
to disrupt Aβ aggregation. A different approach has utilized
the so-called surface tension-modifying peptides106 that actually increased the rate of Aβ fibril formation several-fold. It
remains to be seen if such peptides prevent the build up of
the toxic soluble intermediates by sequestering Aβ in the fibril state.
Thus, it is clear that the considerable efforts in the rational
design of Aβ-targeting molecules based on the parent Aβ sequence have been quite fruitful in providing a large class of
compounds with different modes of activity.107 These peptidomimetic molecules by themselves or with further modifications
provide a class of reagents that may help elucidate the mechanism of amyloid aggregation, perhaps by trapping intermediates, as well as providing inroads into the design of diagnostic
and therapeutic reagents.
3. Targeting Aβ with Antibodies
Antibodies, because of their specificity and conformation
dependence, have been attractive choices for potential therapeutic strategies for the treatment of AD. They are now also
being used to distinguish between fibrils and prefibrillar intermediates in the aggregation pathway. The recent developments in Aβ immunotherapy and in the use of site-directed antibodies as tools for understanding the amyloid aggregation
pathway is elaborated in the following two subsections:
Aβ Immunotherapy
Antibodies generated against Aβ1–42 were shown to lower
cerebral amyloid plaques in mouse models.108 However, a
clinical trial using Aβ1–42 fibrils for active immunization was
halted when ~6 % of the patients developed meningoencephalitis,109, 110 possibly due to a potent T-cell mediated immune response. To avoid the risk of such an adverse autoimmune response and to develop safer vaccines, newer strategies are
being tested in Aβ immunotherapy using the N terminus Aβ1–15
fragment which has been demonstrated to lack T-cell reactivity in mice and humans.111, 112 As a monovalent linear peptide
would not be an effective immunogen, Agadjanyan et al. synthesized the Aβ1–15 fragment in tandem with an HLA DR binding peptide (PADRE).113 PADRE is a 13-residue nonnatural
peptide that is a potent T-cell epitope. PADRE-Aβ1–15 was synthesized on a multiple antigenic peptide (MAP) platform to enhance the immune response by a multivalent effect. Antibodies induced by PADRE-Aβ1–15-MAP were specific to Aβ and
did not bind to the MAP backbone or PADRE. These antibodies prevented Aβ fibrillization and the splenocytes from mice
showed T-cell stimulation only to PADRE and not to Aβ T-cell
epitopes. In a similar approach, bacterial thioredoxin (Trx) was
used as a scaffold to link four repeats of Aβ1–15.114 The anti-Trx
(Aβ15)4 antibody generated against this epitope bound to Aβ1–
42 fibrils and oligomers but not monomers and reduced Aβ pathology in transgenic AD mice.
In a complementary approach, Maier et al. have tested peptide immunogens consisting of tandem repeats of di-lysine
linked Aβ1–15 sequences (Aβ1–15-KK-Aβ1–15) and found them to
be more effective in boosting the immune response as com-
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Figure 3. Production of antibodies that specifically bind Aβ1–40 oligomers. In the dot blot assay, anti-oligomer antibody (A11) binds only to (1) the
oligomeric intermediate of Aβ40 and does not show reactivity against (2) Aβ40 fibrils or (3) Aβ40 monomers, whereas 6E10 recognized all species of
Aβ.

pared to Aβ1–15 itself.42 Of these, Aβ1–15-KK-Aβ1–15 and RGDAβ1–15-KK-Aβ1–15 significantly reduced Aβ plaque load in transgenic AD mice without splenocyte proliferation.115 Animals
immunized with Aβ1–15-KK-Aβ1–15 also showed improved acquisition of memory as compared to the controls. Thus, these
new studies using active immunization show much promise
but will ultimately have to demonstrate safety and efficacy in
clinical trials. It would also be interesting to pursue the in vitro
study of the individual antibodies elicited by these active immunization regimes and clearly establish the molecular mechanism for their interactions with Aβ.
Antibodies as probes of Aβ intermediates
Antibodies are also emerging as useful chemical probes
for delineating the steps in Aβ assembly. As mentioned earlier,
many reports suggest the soluble oligomers and not the fibrils
are the toxic species,13 thus the interaction of specific antibodies with Aβ are being used to directly probe such intermediate
species for a better understanding of the aggregation pathway.
O’Nuallain and Wetzel described the generation of two conformation-specific antibodies, WO1 and WO2 that bound to Aβ1–
40 fibrils but not soluble Aβ species, even in the presence of
a large excess of Aβ1–40 monomers.116 These antibodies were
also able to bind amyloid fibrils of other proteins, which again
strongly suggests that the final fibrillar form of Aβ is common
to numerous proteins that form fibers. To generate polyclonal
antibodies against the so-called Aβ-derived diffusible ligands
(ADDLs), the toxic soluble oligomers of Aβ1–42, Lambert et al.
incubated Aβ solution for 48 h at 4 °C, centrifuged at 14 000 g
for 10 min, and used the supernatant (0.24 mg Aβ mL−1) as an
immunogen.117 This supernatant (defined as ADDL preparation) was free of amyloid fibrils and contained a mixed population of spherical oligomers and monomers of Aβ (as observed

by AFM). The antibodies produced recognized trimers, tetramers, and surprisingly also fibrils of Aβ1–42 in dot-blot assays.
At higher concentrations the antibody was also found to bind
monomers. A more specific antibody probe against such oligomers was prepared in a controlled fashion by Kayed et al.118
They reacted gold nanoparticles with a C-terminal thioester
containing Aβ1–40 to synthesize micellar mimetics of Aβ oligomers (Figure 3). These micellar mimetics were similar in size
when compared to the soluble intermediates and were used
to immunize rabbits. The anti-oligomer antibody generated did
not react with monomers or fibrils of Aβ1–40, but was reported
to exclusively precipitate Aβ1–40 oligomers in dot-blot assays.
The smallest oligomeric species recognized by this antibody
had an apparent molecular weight of 40 kDa on size exclusion
chromatography, which corresponds to an octamer of Aβ1–40.
The anti-oligomer antibody is now commercially available from
Invitrogen and is being utilized to delineate the mechanism of
small molecules that influence Aβ oligomerization, which is discussed in Section 5 of this review.42 Again, it is surprising that
this new anti-oligomer antibody also recognized soluble intermediates of other amyloidogenic proteins and peptides. These
results in conjunction with the Aβ fibril targeting antibody suggest that not only are the final fibrillar structures similar for different proteins but so are many of the intermediates.
4. Targeting Amyloid with in vitro Selected Peptides and
Proteins
Though antibodies are clearly the first established choice
for targeting proteins and peptides, phage displayed peptides
and protein scaffolds have also emerged as an alternate route
for targeting Aβ.119, 120 Phage display approaches generally
enrich for an immobilized protein of interest and a complicated
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Figure 4. The general scheme for selecting mirror image peptides is shown.
Table 4. Peptides selected for Aβ binding.
Selected Peptide Inhibitors
Peptide
DWGKGGRWRLWPGASGKTEA
PGRSPFTGKKLFNQEFSQDQ
D-QSHYRHISPAQV
FYLKVPSSLHHHH
GRDKLVFFHHHH
NYSKMIFSHHHH
HNHKLVFFHHQH
MAQTFWLSIQGKTLYWQIRIYAID-

Results
Binds Aβ in vitro with a Kd of 60 nM by ELISA
Stains Aβ deposits
Binds Aβ in vitro with a Kd of 400 nM by fluorescence
Prefers monomeric Aβ
Prefers monomeric Aβ
Prefers aggregated Aβ
Prefers aggregated Aβ
Inhibits fibril formation of Aβ

immunization protocol is not necessary. Results in this area
are tabulated (Table 4) and discussed in this section.
In one of the earliest studies in this area, a library of 20
residue peptides was used to select for Aβ1–40 binding using
phage display.121 Only two peptides were identified from this
selection and were shown to be capable of staining Aβ deposits. The sequences suggested an aromatic rich motif: (W/F)
X5(W/F)X2/3(W/F) which sometimes contained proline residues
suggesting a turn conformation.
Mirror-image phage display allowing for the eventual identification of D-amino acid peptides (Figure 4) has been utilized
for the discovery of peptides which bind Aβ.125 In this strategy
a synthetic D-amino acid version (enantiomer) of the target is
immobilized, against which a library containing L-amino acid
peptides is selected. Once L-amino acid binders are identified,
their D-enantiomers are synthesized and interrogated for binding to the L-amino acid target. This is an elegant approach for
the development of peptide inhibitors that are resistant to proteolytic cleavage. Using this approach Wiesehen and co-workers immobilized the full length D-enantiomer of Aβ1–42 and selected binders from a phage-displayed peptide library.122 The
D-enantiomer of the most prevalent sequence from this selection, D-QSHYRHISPAQV, binds the natural L-enantiomer of
Aβ (1–42) with an apparent dissociation constant of 400 nM,
though the stoichiometry of the complex remains to be ex-

Ref.
121
121
122
123
123
123
123
124

plored in detail. Appropriately labeled analogues of this peptide were also shown to be effective in staining Aβ deposits in
brain tissues. However, the effect of this peptide on Aβ aggregation has not been determined to date.
Phage display using the KLVFF core motif was used to
identify peptides which bound different species in the Aβ aggregation pathway.123 Two libraries were used to assess the
effect of polar residues on binding and the sequence requirements of the core motif. Both libraries were screened against
aggregated and monomeric Aβ. Surprisingly, peptides selected
for binding to the monomeric species did not effect the aggregation rate whereas those selected for binding to the aggregated species did. The ability of these peptides to promote
aggregation correlated with their relative affinities for the N terminus of Aβ. The observation that peptides can be selected
to bind specifically to different intermediates in the Aβ aggregation pathway opens up the possibility of producing tractable reagents for deciphering amyloid aggregation kinetics and
thermodynamics.
We have recently utilized phage display to isolate variants
of a small β-sheet scaffold126 that likely binds to intermediates
in the aggregation pathway of Aβ.124 In this selection scheme
(Figure 5) a phage-displayed library containing eight randomized residues on the first two β-strands of the small IgG
binding protein, HTB1, was generated. This library was first

Figure 5. Selection of β-sheet displaying small proteins (HTB1 variants) which bind Aβ. Eight positions on two β-sheets are randomized. An initial
structural selection, using the helical face, against IgG maintains the native fold. Subsequent rounds of selection for Aβ-binding, using the β-sheet
face, yielded the TJ10 variant.
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enriched for proteins that maintain the parent fold by IgG sebiophysical studies in this arena that the mode of interaction of
lection and subsequently selected against Aβ1–40 (Figure 5).
these dyes with amyloid aggregates is still not clearly underSeveral proteins were isolated, notably one of these small
stood, though solid-state NMR studies may soon establish a
molecular description of these interactions. Many reports indiβ-sheet rich proteins, TJ10, maintained its structure and was
cate that these dyes selectively interdigitate between amyloid
shown to inhibit Aβ1–40 aggregation in a stoichiometric manner.
strands and it was believed that these dyes exclusively bind fiInitial dynamic light scattering experiments suggest that TJ10
interacts and likely traps soluble oligomers of Aβ1–40 that range
brils with β-sheet conformation. However, a report showed that
from 10–300 nm in diameter.
Congo red could also form complexes with proteins having α,
This approach has the potential for providing a structural
α/β and β conformations.137 Analogous studies with ThT, the
handle on an Aβ1–40 binding protein motif not easily realizable
reagent of choice for following Aβ aggregation, need to be carried out as many reports on Aβ inhibition are based on these
with smaller unstructured peptides. The results from this selecassays. Congo red and ThT have also been shown to inhibit
tion also correlate well with the previously described selections
fibril formation42, 138 at higher concentrations. Thus chemical
with both antibodies and peptides, where aromatic residue
derivatives of these dyes, with enhanced permeability through
rich sequences are strongly favored. From a molecular perspective this may suggest a possible common binding mode
the blood-brain barrier, have been synthesized (Table 5) as
for Aβ where aromatic residues in suitable protein and pepin vivo imaging probes.139–141 Results from these ongoing
tide scaffolds interdigitate with an existing core Aβ structure.
studies may help in early diagnosis of AD.
In many of the above cases,
experiments need to be perTable 5. Chemical derivatives of Congo red and ThT used as imaging probes for detecting amyloid plaque.
formed to explore whether
these Aβ selected peptides
and proteins also target multiple amyloidogenic proteins
as observed in the case of
the previously described
antibodies.
Fluorogenic and radiolabeled derivatives of Congo red and ThT
5. Targeting Aβ with Small
Molecules
In the past decade numerous organic compounds
have been studied for the inhibition of amyloid aggregation as a direct therapeutic
strategy for the treatment of
amyloidosis. These include
surfactants,127 Cu/Zn chelators,128 known bioactive molecules (for example, apomorphine,129 rifamycine,130
curcumin,131 porphyrins,130),
and sulfonated dyes such
as Congo red and its derivatives.132 In fact, Congo
red was the first small molecule reported to bind to amyloid in tissue sections and
exhibited the characteristic
yellow-green
birefringence
under cross polarizers.133, 134
Later thioflavin T (ThT) and
S (ThS) were also shown to
characteristically stain amyloid deposits.135, 136 These
two dyes are the classic reagents for determining characteristic β-sheet mediated
fibrillization seen for all amyloid forming proteins. It
speaks to the difficulty in the

* represents the atom radiolabeled.
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Not surprisingly perhaps, many reported small molecule inhibitors are similar to Congo Red and ThT, in that they are planar and aromatic. The possible mode of interaction with Aβ
has been reviewed by Porat et al.142 It is also interesting to
again note that many of the proteins and peptides selected to
bind Aβ also contain a preponderance of aromatic residues.
It is tempting to speculate that both small molecules and aromatic amino acid residues can intercalate within grooves created by β-sheets in both the soluble oligomeric forms as well
as the large fibrils.
Many studies with small molecules have focused on the
inhibition of fibril formation, however Blanchard et al. have
screened a library of >3000 small molecules in an attempt to
discover compounds that reduce the β-sheet content of preformed fibrils of Aβ42.143 Of the six lead compounds, 4,5-dianilinophthalimide (DAPH) was reported to effectively reduce Aβ1–42 fibrils when incubated with preformed Aβ1–42
fibrils in equimolar amounts for 24 h. However, as is common to this field, the authors utilized the standard ThT assay
in their screens, where there is the possibility of unintentionally isolating small molecules that interfere with ThT binding
rather than disaggregate preformed amyloid fibers. Experiments have shown that many compounds (for example, melatonin, β-cyclodextrin, phthalocyanine, dimethyl yellow, and fenofibrate) competitively prevent the binding of ThT to the fibrils
giving a possible false positive with regard to inhibition of Aβ
aggregation.42 However, elegant work by Lockhart et al. has
shown that Congo red-type molecules do not share the same
binding site as ThT on fibrils.146, 147 Competition studies to determine the binding preferences of small molecule inhibitors
and these classic ligands should be performed before conclusions regarding mechanisms of action are drawn.
With mounting evidence implicating soluble oligomeric intermediates as the toxic species, it is perhaps not sufficient to
identify small molecule drug candidates that inhibit fibrillization but rather those that prevent toxicity. This is perhaps best
exemplified by a study where naphthalene sulfonates were
shown to inhibit fibril formation but stabilized the toxic oligomers.148 In another example, the hydroxyaniline derivatives,
RS-0406 (reported to inhibit aggregation)149 and RS-0466

in

C h e m M e d C h e m 2 (2007)

(reported to have no effect on aggregation)145 (Table 6) were
shown to inhibit the formation of SDS-stable Aβ oligomers in
living cells.144
The most comprehensive effort in this area is a recent report by Glabe and co-workers,42 where they systematically
evaluated 40 previously reported small molecule Aβ inhibitors.
This study attempts to clarify the role of the small molecule inhibitors in terms of their ability to interact with Aβ oligomers or
fibrils or both. A battery of assays were utilized, that included
ThT fluorescence, turbidimetry, dot-blot/western blot assays
with oligomer specific antibodies (A11), and TEM to understand the aggregation kinetics and minimize the effect of any
artifact related to a particular assay. Based on their results,
Necula et al. categorized their screens into three classes:
class I consisted of compounds that inhibited oligomerization
but not fibrillization, class II consisted of compounds that inhibited both oligomerization and fibrillization and class III were
compounds that inhibited fibrillization and not oligomerization
(Table 7).42
The data suggest that it may be possible to selectively inhibit “off-pathway” intermediates and/or fibril formation. This
study agrees quite well with a screen of small molecules
against tau filament formation and Aβ1–40 aggregation reported
by Taniguchi et al.130 A comparison of the IC50 values reported
by the two groups showed very similar trends in inhibitory activity and thus provides the field with a useful set of standard
molecules (Figure 6). Interestingly, the A11 antibody is crossreactive with a wide variety of oligomeric species,118 indicating
that inhibitors may have general applicability across many different aggregation diseases.
A clever approach combines small molecule targeting with
natural bystander proteins to prevent amyloid aggregation.150
Gestwicki et al. designed a bifunctional molecule by covalently tethering a synthetic ligand (SLF) to Congo red (CR)
(Figure 7 a).150 CR at one end interacts with aggregated Aβ
whereas the synthetic ligand recruits a molecular chaperone
(FKBP), providing the small molecule derivative with the necessary steric bulk to disrupt Aβ aggregation. This approach
significantly enhanced the potency of CR by several-fold (IC50
of CR, 2.9 μM; IC50 SLF-CR/FKBP, 0.52 μM). SLF-CR/FKBP

Table 6. Hydroxyaniline derivatives inhibited Aβ oligomerization in APP-expressing CHO cells.144

6-ethyl-N,N′-bis(3-hydroxyphenyl)[1,3,5]triazine-2,4-diamine 	
(RS-0466)

N′-bis(3-hydroxyphenyl)pyridazine-3,6-diamine
(RS-0406)

Comparison of results for RS-0466 and RS-0406
Nakagami et al.145						Walsh et al.144
RS-0466 did not affect Aβ fibrillization when measured by ThT 	
These results were reproduced by Walsh et al. in their in vitro
assay, RS-0406 inhibited fibrillization, and also disassembled 	
studies.
preformed Aβ fibrils.
 	 
RS-0466 and RS-0406 inhibited Aβ induced cytotoxicity in HeLa 	
Both compounds prevented formation of Aβ oligomers in
cells and blocked impairment of long-term potentiation in rat 	
living cells (7A2 cells) and blocked Aβ-mediated LTP.
hippocampal slices.
 	 
How these compounds inhibited Aβ induced cytotoxicity was not 	
It was shown that RS-0466 and RS-0406 inhibited the formation
studied.
of new oligomers, they did not affect preformed Aβ oligomers.
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Table 7. Small molecules categorized into classes based on their effect on Aβ1–42 aggregation.42
Class I (Compounds that inhibit oligomerization but do not inhibit fibrillization)

Class II (Compounds that inhibit both oligomerization and fibrillization)
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Table 7. Small molecules categorized into classes based on their effect on Aβ1–42 aggregation42 (continued).

Class III (Compounds that inhibit fibrillization but do not inhibit oligomerization)

treated neurons displayed normal morphology and high cell
viability (~70 %). To further increase the potency of the bivalent inhibitor, the authors varied the linker length between SLF
and CR. Of the three new molecules created (Figure 7 b), SLFBenz-CR/FKBP was most effective with an IC50 of 50 nM. The
authors did observe the presence of small aggregates in electrophoretic analysis and AFM images in Aβ samples treated
with their bifunctional molecule.
Finally a screen has been developed for the discovery of
Aβ aggregation inhibitors in E. coli cells.151 This approach
takes advantage of a green fluorescent protein (GFP) based
assay152 where the fluorescence of GFP is compromised by
attachment of Aβ, presumably due to GFP-misfolding mediated by Aβ aggregation. GFP folding and fluorescence is recovered upon treatment of the E. coli with small molecules that
likely disrupt Aβ aggregation. This may be a useful approach
for the rapid screening of small molecule Aβ inhibitors and
could eventually be used in more permeable mammalian cells.
Overall, the small molecule approach to Aβ aggregation inhibition is clearly poised to provide new and useful reagents
for in vivo diagnostics as therapeutic applications are already
being demonstrated for analogues of classic Aβ binders such
as Congo Red and ThT. The existing small molecules are also
being probed for their ability to interact with different amyloid
species along the fibrillization pathway, which when correlated
with cellular toxicity studies will likely provide useful protocols
for evaluating new anti-Aβ molecules as they are identified.

Figure 6. A comparison of the IC50 values reported by Taniguchi
et al.130 and Necula et al.42 for the inhibition of Aβ aggregation by small
molecules.
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Summary
In this review we have aimed
to provide a comprehensive
view of the rapidly growing molecular toolbox at our disposal
for targeting Aβ. We have described a wide range of molecules that target Aβ, including
natural proteins, peptides, peptidomimetics, and small molecules. We have also described
recent approaches for selections and screens for developing Aβ targeting antibodies, proteins, and peptides
that have been shown to interact with Aβ oligomers and fibrils and influence aggregation
kinetics. These new strategies
and the resulting molecules being discovered provide a starting point for analogue synthesis that should help in furthering
our understanding of the mechanism of Aβ aggregation and
ultimately aid in reducing cellular toxicity. Moreover, many
of these new approaches may
be applied to other amyloidogenic diseases. These molecules provide new and interesting design opportunities as
seen in the case of the novel
small molecule directed chaperones. Opportunities clearly exist
for utilizing the described small
molecules and peptides discovered to date for decorating discrete multivalent dendrimers to
provide new multivalent entities for targeting both oligomers
and fibrils.93, 153, 154 Thus with
this growing toolbox in hand,
new methods for the molecular
design of diagnostic and therapeutic agents will clearly be
forthcoming.
Outlook

Figure 7. a) Blocking Aβ fibrillization using a bifunctional small molecule that binds to FKBP to increase the steric bulk of the molecule. b) Adding linkers into SLF-CR improves inhibition of aggregation and toxicity.

The study of the aggregation
pathway of Aβ is a difficult and
challenging endeavor and future
work in targeting Aβ will necessitate the development of sensitive analytical methods that
continue to clarify molecular
mechanisms for the pathophysiology of Alzheimer’s disease.
Furthermore, new biophysical
studies must aim to correlate

1690
in vivo toxicity with in vitro aggregation models to allow for accurate interpretation of the mechanism of action of the molecules that are currently available. From a molecular design
perspective, the many ligands that we have described should
be amenable to further chemical functionalization with appropriate imaging agents to develop new and powerful in vitro and
in vivo assays that target different species in the fibrillization
pathway. This approach will allow for the development of molecules that target specific Aβ assemblies and correlate them to
disease outcomes. As an example, many of the reported small
molecules that target oligomers and fibrils, will likely be amenable to radioisotope incorporation for in vivo diagnostic imaging with PET (Positron Emission Tomography)155 and SPECT
(Single Photon Emission Computerized Tomography).139, 156
Thus at the current time we are clearly at the threshold of discovering new diagnostic tools as well as therapeutic molecules
that may help ameliorate the devastating neurological effects
of Alzheimer’s disease.
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